Literature Review on Individuals with Neurologic or Neurodevelopment Conditions and Risk of Serious Influenza-Related Complications
An Advisory Committee Review: National Advisory Committee on Immunization (NACI). The findings of the present rapid literature review are consistent with the preliminary evidence supporting children and adults with neurologic and neurodevelopment conditions as groups at risk for influenza-related complications and hospitalization.
Pour assurer l’immunisation des enfants immunodéprimés, il faut adopter des stratégies de vaccination visant à maximiser la protection tout en minimisant les méfaits. Les dispensateurs de soins de première ligne et les spécialistes qui s’occupent de ces enfants partagent la responsabilité de la vaccination. Des lignes directrices détaillées figurent dans la version à jour du Guide canadien d’immunisation, mais les principes généraux sont exposés dans le Point de pratique publié par la Société canadienne de pédiatrie.
Mise à jour sur la vaccination contre la méningococcie invasive chez les enfants et les adolescents canadiens
Invasive meningococcal disease (IMD) is serious, often resulting in fulminant sepsis or meningitis. IMD in Canada is primarily attributable to serogroups B and C. There are routine programs for serogroup C vaccine at 12 months of age, with some jurisdictions routinely providing additional earlier doses. Adolescents routinely receive a booster dose of serogroup C vaccine or of a quadrivalent (serogroups A, C, W and Y) vaccine. Serogroup B vaccines are not recommended for routine use pending further data on the efficacy and duration of protection from the available vaccine. However, children at increased risk for IMD should start immunization for serogroups B and C as soon as possible, assuming that they are at least 2 months of age.
Mise à jour sur l’immunisation maternelle : vaccination universelle avec le vaccin dcaT chez les femmes enceintes au Canada
Enregistrement (vidéo) du webinaire proposé par la SOGC, avec la Dre. Vanessa Poliquin.
NACI Literature Review on the Comparative Effectiveness and Immunogenicity of Subunit and Split Virus Inactivated Influenza Vaccines in Adults 65 Years of Age and Older
Subunit and split virus inactivated influenza vaccines are two commonly used types of seasonal influenza vaccines, and continue to dominate the market in Canada. Although these two formulations of influenza vaccine have been available for many decades, NACI has not previously conducted a literature review to investigate the comparative vaccine effectiveness of these different formulations. A difference in vaccine effectiveness between these formulations would be especially important for older adults (65 years of age or older), since there is evidence that older adults experience more severe illness due to influenza and have reduced vaccine effectiveness compared to younger adults. To address this gap, NACI conducted a literature review to examine the vaccine effectiveness and immunogenicity of unadjuvanted, standard dose subunit inactivated influenza vaccines compared to unadjuvanted, standard dose split virus inactivated influenza vaccines in adults 65 years of age and older.
Poster: Immunization against pertussis during pregnancy is safe and helps reduce the risk of disease in infants.
Immunization rates in Canada are suboptimal. Strategies such as making immunization mandatory for child care or school entry and financial incentives are used in other countries. Additional strategies that could work in the Canadian context include requiring accurate immunization records at school entry, implementing immunization registries at the provincial/territorial level, educating parents and school-aged children about vaccine-preventable diseases and making it more convenient for parents to ensure their children are fully immunized.